築友智造科技(00726.HK)去年銷售合同額按年增長119%
築友智造科技(00726.HK)公佈,集團預製裝配式建築構件及產品的產量截至去年12月底止年度按年增加約40%,至43.03萬立方米,而集團預製裝配式建築構件及產品的銷量按年增長約33%至41.66萬立方米。
集團去年銷售合同額按年增加約119%至約46.69億元人民幣(下同)。其中預製裝配式建築構件及產品的銷售合同額按年增加約74%至約25.01億元。
公司指出,產量、銷量及合同額的增長主要來自全國各地裝配式建築產業受碳中和政策加速落地推動需求增長;集團裝配式PC構件及產品產能的快速提升,規模化優勢持續發力;全產業鏈業務服務能力突顯,品牌聲譽獲市場及客戶持續認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.